Drug intelligence / Profile preview

JAR914

Development stage: Unknown
Lead developer: JAR of Hope
Administration: Intravenous

Overview

JAR914 is an investigational therapeutic being developed by JAR of Hope for **Duchenne muscular dystrophy**, a rare, progressive, and fatal muscle-wasting disorder. Based on the provided source context, JAR914 had an FDA-cleared IND in March 2021 to begin a small clinical study in up to 12 children focused on safety and efficacy. The exact molecular composition, modality, route, and target have not been clearly disclosed in the provided materials, so its precise mechanism of action cannot be stated with confidence from the available evidence.

Beyond the preview

Go deeper on JAR914.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JAR914.

Explore the full profile